

Appendix 1 (as supplied by the authors): Decrement in utility for health states in the economic model

Health state	Decrement*	Measurement technique
Myocardial infarction, year of event ¹	-0.0409222	EuroQol-5D
Myocardial infarction, subsequent yrs ²	-0.012	EuroQol-5D
Angina, year of event ¹	-0.0411989	EuroQol-5D
Angina, subsequent yrs ¹	-0.024	EuroQol-5D
Congestive heart failure, year of event ²	-0.0546	EuroQol-5D
Congestive heart failure, subsequent yrs ²	-0.018	EuroQol-5D
Stroke, year of event ¹	-0.0523513	EuroQol-5D
Stroke, subsequent yrs ¹	-0.040	EuroQol-5D
Peripheral vascular disease ³	-0.021	EuroQol-5D
Microalbuminuria ⁴	-0.012	EuroQol-5D
Gross proteinuria ⁵	-0.017	Quality of well being — self administered
Dialysis ^{6,7,8}	-0.16	EuroQol-5D
Functioning kidney transplant ^{6,7,8}	-0.03	Standard gamble
Diabetic retinopathy ¹	-0.0155836	EuroQol-5D
Blindness and low Vision ¹	-0.0497859	EuroQol-5D
Cataract ¹	-0.0170832	EuroQol-5D
Macular edema ¹	-0.0170832	EuroQol-5D
Neuropathy ¹	-0.0243702	EuroQol-5D
Active uninfected diabetic ulcer ⁹	-0.09	Time trade off
Active infected diabetic ulcer ⁹	-0.14	Time trade off
Amputation ¹⁰	-0.266	EuroQol-5D
Severe hypoglycemic episode requiring assistance ¹¹	-0.5485	EuroQol-5D
Mild/moderate hypoglycemic episode ¹¹	-0.167	EuroQol-5D

*Applied for 1-year, except for hypoglycemic episodes and ulcers

References

1. Consumer price index. The Daily. Ottawa (ON). Statistics Canada; 2008. Available: www.statcan.ca/Daily/English/080219/d080219a.htm (accessed 2008 Jun. 20).
2. Drummond MF, Sculpher MJ, Torrance GW, et al. *Methods for the economic evaluation of health care programmes*. 3rd ed. Oxford (UK): Oxford University Press; 2005.
3. Manns B, Johnson JA, Taub K, et al. Quality of life in patients with end-stage renal disease over time: the impact of dialysis modality and other important determinants [working paper 02-05]. Edmonton (AB): Institute of Pharmaco-Economics; 2002 Available: www.ihe.ca/documents/2002-05paper.pdf (accessed 2007 Jul 23).
4. Redekop WK, Koopmanschap MA, Stolk RP, et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. *Diabetes Care* 2002;25:458-63.
5. *EQ-5D: a standardised instrument for use as a measure of health outcome*. Rotterdam (The Netherlands): Euroqol; 2007. Available: www.euroqol.org (accessed 2008 Nov. 27).
6. Caro J, Migliaccio-Walle K, Ishak KJ, et al. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. *BMC Cardiovasc Disord* 2005;5:14.
7. O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. *BMC Health Serv Res* 2003;3:7.
8. Kiberd BA, Larson T. Estimating the benefits of solitary pancreas transplantation in nonuremic patients with type 1 diabetes mellitus: a theoretical analysis. *Transplantation* 2000;70:1121-7.
9. Redekop WK, Stolk EA, Kok E, et al. Diabetic foot ulcers and amputations: estimates of health utility for use in cost-effectiveness analyses of new treatments. *Diabetes Metab* 2004;30:549-56.
10. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). *Med Decis Making* 2002;22:340-9.
11. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. *Med Decis Making* 2006;26:410-20.